{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:20:04Z","timestamp":1791350404778,"version":"4.3.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T00:00:00Z","timestamp":1475020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11940-016-0426-1","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T07:22:21Z","timestamp":1475047341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bioavailable Trace Metals in Neurological Diseases"],"prefix":"10.1007","volume":"18","author":[{"given":"Aur\u00e9lia","family":"Poujois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Devedjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Woimant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Duce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"key":"426_CR1","unstructured":"Fergusson JE. The heavy elements: chemistry, environmental impact and health effects. In: Fergusson JE, editor. Oxford: Pergamon Press; 1990."},{"issue":"2\u20133","key":"426_CR2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12026-013-8403-1","volume":"56","author":"CA Shaw","year":"2013","unstructured":"Shaw CA, Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res. 2013;56(2\u20133):304\u201316.","journal-title":"Immunol Res"},{"key":"426_CR3","doi-asserted-by":"crossref","unstructured":"Andersen O, Aaseth J. A review of pitfalls and progress in chelation treatment of metal poisonings. J Trace Elem Med Biol. 2016.","DOI":"10.1016\/j.jtemb.2016.03.013"},{"issue":"1","key":"426_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF03161007","volume":"2","author":"PK Sethi","year":"2006","unstructured":"Sethi PK, Khandelwal D. Cadmium exposure: health hazards of silver cottage industry in developing countries. J Med Toxicol. 2006;2(1):14\u20135.","journal-title":"J Med Toxicol"},{"issue":"1","key":"426_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1503\/cmaj.060790","volume":"176","author":"E Brodkin","year":"2007","unstructured":"Brodkin E et al. Lead and mercury exposures: interpretation and action. CMAJ. 2007;176(1):59\u201363.","journal-title":"CMAJ"},{"issue":"18","key":"426_CR6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMra022471","volume":"349","author":"TW Clarkson","year":"2003","unstructured":"Clarkson TW, Magos L, Myers GJ. The toxicology of mercury\u2014current exposures and clinical manifestations. N Engl J Med. 2003;349(18):1731\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"426_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtemb.2013.09.006","volume":"28","author":"N Krebs","year":"2014","unstructured":"Krebs N et al. Assessment of trace elements in human brain using inductively coupled plasma mass spectrometry. J Trace Elem Med Biol. 2014;28(1):1\u20137.","journal-title":"J Trace Elem Med Biol"},{"key":"426_CR8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2008.10.056","volume":"1248","author":"BS Choi","year":"2009","unstructured":"Choi BS, Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res. 2009;1248:14\u201321.","journal-title":"Brain Res"},{"issue":"3","key":"426_CR9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.taap.2011.02.003","volume":"256","author":"AD Monnot","year":"2011","unstructured":"Monnot AD et al. Regulation of brain copper homeostasis by the brain barrier systems: effects of Fe-overload and Fe-deficiency. Toxicol Appl Pharmacol. 2011;256(3):249\u201357.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"9","key":"426_CR10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1039\/c0mt00006j","volume":"2","author":"S Lutsenko","year":"2010","unstructured":"Lutsenko S, Bhattacharjee A, Hubbard AL. Copper handling machinery of the brain. Metallomics. 2010;2(9):596\u2013608. Summary of the current knowledge about cerebral copper levels and actions. Fine description of the molecules involved in maintaining copper homeostasis in the brain.","journal-title":"Metallomics"},{"key":"426_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jtemb.2014.05.003","volume":"29","author":"A Ahuja","year":"2015","unstructured":"Ahuja A et al. Copper mediated neurological disorder: visions into amyotrophic lateral sclerosis, Alzheimer and Menkes disease. J Trace Elem Med Biol. 2015;29:11\u201323.","journal-title":"J Trace Elem Med Biol"},{"key":"426_CR12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/nyas.12347","volume":"1315","author":"H Zischka","year":"2014","unstructured":"Zischka H, Lichtmannegger J. Pathological mitochondrial copper overload in livers of Wilson\u2019s disease patients and related animal models. Ann N Y Acad Sci. 2014;1315:6\u201315.","journal-title":"Ann N Y Acad Sci"},{"key":"426_CR13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/B978-0-7020-4087-0.00057-7","volume":"120","author":"F Woimant","year":"2014","unstructured":"Woimant F, Trocello JM. Disorders of heavy metals. Handb Clin Neurol. 2014;120:851\u201364. Insightful review of the current clinical, diagnostic and treatment challenges in heavy metals disorders.","journal-title":"Handb Clin Neurol"},{"issue":"Pt 5","key":"426_CR14","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/brain\/awt035","volume":"136","author":"AJ Coffey","year":"2013","unstructured":"Coffey AJ et al. A genetic study of Wilson\u2019s disease in the United Kingdom. Brain. 2013;136(Pt 5):1476\u201387.","journal-title":"Brain"},{"issue":"17","key":"426_CR15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1212\/WNL.0b013e3182a95883","volume":"81","author":"JM Trocello","year":"2013","unstructured":"Trocello JM et al. Extensive striatal, cortical, and white matter brain MRI abnormalities in Wilson disease. Neurology. 2013;81(17):1557.","journal-title":"Neurology"},{"issue":"10","key":"426_CR16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/jnnp.2009.204651","volume":"82","author":"JM Trocello","year":"2011","unstructured":"Trocello JM et al. Corpus callosum abnormalities in Wilson\u2019s disease. J Neurol Neurosurg Psychiatry. 2011;82(10):1119\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"23\u201324","key":"426_CR17","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cca.2011.08.019","volume":"412","author":"S Balkhi El","year":"2011","unstructured":"El Balkhi S et al. Relative exchangeable copper: a new highly sensitive and highly specific biomarker for Wilson\u2019s disease diagnosis. Clin Chim Acta. 2011;412(23\u201324):2254\u201360.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"426_CR18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1474-4422(14)70190-5","volume":"14","author":"O Bandmann","year":"2015","unstructured":"Bandmann O, Weiss KH, Kaler SG. Wilson\u2019s disease and other neurological copper disorders. Lancet Neurol. 2015;14(1):103\u201313. A comprehensive review of Wilson\u2019s disease including its phenomenology, pathophysiology, imaging findings and treatment.","journal-title":"Lancet Neurol"},{"issue":"1","key":"426_CR19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2005.087262","volume":"56","author":"U Merle","year":"2007","unstructured":"Merle U et al. Clinical presentation, diagnosis and long-term outcome of Wilson\u2019s disease: a cohort study. Gut. 2007;56(1):115\u201320.","journal-title":"Gut"},{"issue":"8","key":"426_CR20","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.cgh.2013.03.012","volume":"11","author":"KH Weiss","year":"2013","unstructured":"Weiss KH et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013;11(8):1028\u201335. e1-2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"426_CR21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ene.12348","volume":"21","author":"A Czlonkowska","year":"2014","unstructured":"Czlonkowska A et al. D-penicillamine versus zinc sulfate as first-line therapy for Wilson\u2019s disease. Eur J Neurol. 2014;21(4):599\u2013606.","journal-title":"Eur J Neurol"},{"issue":"4","key":"426_CR22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/j.gastro.2010.12.034","volume":"140","author":"KH Weiss","year":"2011","unstructured":"Weiss KH et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology. 2011;140(4):1189\u201398. e1.","journal-title":"Gastroenterology"},{"issue":"2","key":"426_CR23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.trsl.2009.05.002","volume":"154","author":"GJ Brewer","year":"2009","unstructured":"Brewer GJ et al. Treatment of Wilson\u2019s disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res. 2009;154(2):70\u20137.","journal-title":"Transl Res"},{"issue":"3","key":"426_CR24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2013.10.025","volume":"60","author":"O Guillaud","year":"2014","unstructured":"Guillaud O et al. Long term results of liver transplantation for Wilson\u2019s disease: experience in France. J Hepatol. 2014;60(3):579\u201389.","journal-title":"J Hepatol"},{"issue":"9","key":"426_CR25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/lt.20486","volume":"11","author":"V Medici","year":"2005","unstructured":"Medici V et al. Liver transplantation for Wilson\u2019s disease: the burden of neurological and psychiatric disorders. Liver Transpl. 2005;11(9):1056\u201363.","journal-title":"Liver Transpl"},{"issue":"21","key":"426_CR26","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1039\/c2dt12188c","volume":"41","author":"P Delangle","year":"2012","unstructured":"Delangle P, Mintz E. Chelation therapy in Wilson\u2019s disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators. Dalton Trans. 2012;41(21):6359\u201370.","journal-title":"Dalton Trans"},{"issue":"11","key":"426_CR27","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/gt.2011.186","volume":"19","author":"JL Roybal","year":"2012","unstructured":"Roybal JL et al. Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson\u2019s disease. Gene Ther. 2012;19(11):1085\u201394.","journal-title":"Gene Ther"},{"key":"426_CR28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12422","volume":"1314","author":"SG Kaler","year":"2014","unstructured":"Kaler SG. Translational research investigations on ATP7A: an important human copper ATPase. Ann N Y Acad Sci. 2014;1314:64\u20138. A general and comprehensive review of disorders due to ATP7A dysfunctions.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"426_CR29","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/mt.2011.143","volume":"19","author":"A Donsante","year":"2011","unstructured":"Donsante A et al. ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model. Mol Ther. 2011;19(12):2114\u201323.","journal-title":"Mol Ther"},{"key":"426_CR30","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/B978-0-444-59565-2.00045-9","volume":"113","author":"SG Kaler","year":"2013","unstructured":"Kaler SG. Inborn errors of copper metabolism. Handb Clin Neurol. 2013;113:1745\u201354.","journal-title":"Handb Clin Neurol"},{"issue":"Pt 3","key":"426_CR31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/brain\/awt012","volume":"136","author":"D Martinelli","year":"2013","unstructured":"Martinelli D et al. MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain. 2013;136(Pt 3):872\u201381.","journal-title":"Brain"},{"issue":"1","key":"426_CR32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajhg.2011.11.030","volume":"90","author":"P Huppke","year":"2012","unstructured":"Huppke P et al. Mutations in SLC33A1 cause a lethal autosomal-recessive disorder with congenital cataracts, hearing loss, and low serum copper and ceruloplasmin. Am J Hum Genet. 2012;90(1):61\u20138.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"426_CR33","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00415-013-6963-6","volume":"260","author":"T Teodoro","year":"2013","unstructured":"Teodoro T et al. Recovery after copper-deficiency myeloneuropathy in Wilson\u2019s disease. J Neurol. 2013;260(7):1917\u20138.","journal-title":"J Neurol"},{"key":"426_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12354","volume":"1314","author":"JR Prohaska","year":"2014","unstructured":"Prohaska JR. Impact of copper deficiency in humans. Ann N Y Acad Sci. 2014;1314:1\u20135.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"426_CR35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1600-0609.2008.01050.x","volume":"80","author":"TR Halfdanarson","year":"2008","unstructured":"Halfdanarson TR et al. Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol. 2008;80(6):523\u201331.","journal-title":"Eur J Haematol"},{"issue":"5 Suppl","key":"426_CR36","doi-asserted-by":"crossref","first-page":"1069S","DOI":"10.1093\/ajcn\/67.5.1069S","volume":"67","author":"I Bremner","year":"1998","unstructured":"Bremner I. Manifestations of copper excess. Am J Clin Nutr. 1998;67(5 Suppl):1069S\u201373.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"426_CR37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1004967","volume":"366","author":"RE Fleming","year":"2012","unstructured":"Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348\u201359.","journal-title":"N Engl J Med"},{"issue":"4","key":"426_CR38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.seminhematol.2009.07.001","volume":"46","author":"C Camaschella","year":"2009","unstructured":"Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol. 2009;46(4):371\u20137.","journal-title":"Semin Hematol"},{"issue":"33","key":"426_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000531","volume":"9","author":"G Cairo","year":"2007","unstructured":"Cairo G, Recalcati S. Iron-regulatory proteins: molecular biology and pathophysiological implications. Expert Rev Mol Med. 2007;9(33):1\u201313.","journal-title":"Expert Rev Mol Med"},{"issue":"3","key":"426_CR40","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2007-07-102335","volume":"111","author":"YS Sohn","year":"2008","unstructured":"Sohn YS et al. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood. 2008;111(3):1690\u20139.","journal-title":"Blood"},{"issue":"8","key":"426_CR41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrn3453","volume":"14","author":"TA Rouault","year":"2013","unstructured":"Rouault TA. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci. 2013;14(8):551\u201364.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"426_CR42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1242\/dmm.009019","volume":"5","author":"TA Rouault","year":"2012","unstructured":"Rouault TA. Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech. 2012;5(2):155\u201364.","journal-title":"Dis Model Mech"},{"issue":"7324","key":"426_CR43","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","volume":"468","author":"JN Guzman","year":"2010","unstructured":"Guzman JN et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature. 2010;468(7324):696\u2013700.","journal-title":"Nature"},{"issue":"1","key":"426_CR44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.freeradbiomed.2005.02.034","volume":"39","author":"E Milusheva","year":"2005","unstructured":"Milusheva E et al. Increased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment. Free Radic Biol Med. 2005;39(1):133\u201342.","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"426_CR45","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrn1537","volume":"5","author":"L Zecca","year":"2004","unstructured":"Zecca L et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863\u201373.","journal-title":"Nat Rev Neurosci"},{"key":"426_CR46","doi-asserted-by":"crossref","unstructured":"Hutchinson C. A review of iron studies in overweight and obese children and adolescents: a double burden in the young? Eur J Nutr. 2016.","DOI":"10.1007\/s00394-016-1155-7"},{"key":"426_CR47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphar.2013.00167","volume":"4","author":"ZI Cabantchik","year":"2013","unstructured":"Cabantchik ZI et al. Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol. 2013;4:167.","journal-title":"Front Pharmacol"},{"issue":"2","key":"426_CR48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"D Devos","year":"2014","unstructured":"Devos D et al. Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal. 2014;21(2):195\u2013210. Establishes the therapeutic features of chelation modality in PD translational models and in pilot clinical trials.","journal-title":"Antioxid Redox Signal"},{"key":"426_CR49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphar.2014.00099","volume":"5","author":"S Levi","year":"2014","unstructured":"Levi S, Finazzi D. Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms. Front Pharmacol. 2014;5:99.","journal-title":"Front Pharmacol"},{"issue":"2","key":"426_CR50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.spen.2012.03.007","volume":"19","author":"G Zorzi","year":"2012","unstructured":"Zorzi G et al. Therapeutic advances in neurodegeneration with brain iron accumulation. Semin Pediatr Neurol. 2012;19(2):82\u20136.","journal-title":"Semin Pediatr Neurol"},{"issue":"9","key":"426_CR51","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/mds.23751","volume":"26","author":"G Zorzi","year":"2011","unstructured":"Zorzi G et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord. 2011;26(9):1756\u20139.","journal-title":"Mov Disord"},{"issue":"11","key":"426_CR52","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2011.043018","volume":"96","author":"G Abbruzzese","year":"2011","unstructured":"Abbruzzese G et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica. 2011;96(11):1708\u201311.","journal-title":"Haematologica"},{"issue":"6","key":"426_CR53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.parkreldis.2014.03.002","volume":"20","author":"G Cossu","year":"2014","unstructured":"Cossu G et al. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. Parkinsonism Relat Disord. 2014;20(6):651\u20134.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"426_CR54","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jnr.490270421","volume":"27","author":"JR Connor","year":"1990","unstructured":"Connor JR et al. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res. 1990;27(4):595\u2013611.","journal-title":"J Neurosci Res"},{"issue":"8569","key":"426_CR55","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(87)91361-4","volume":"2","author":"DT Dexter","year":"1987","unstructured":"Dexter DT et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet. 1987;2(8569):1219\u201320.","journal-title":"Lancet"},{"issue":"9","key":"426_CR56","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/mds.23643","volume":"26","author":"G Du","year":"2011","unstructured":"Du G et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson\u2019s disease. Mov Disord. 2011;26(9):1627\u201332.","journal-title":"Mov Disord"},{"issue":"11","key":"426_CR57","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1093\/brain\/awq212","volume":"133","author":"P Peran","year":"2010","unstructured":"Peran P et al. Magnetic resonance imaging markers of Parkinson\u2019s disease nigrostriatal signature. Brain. 2010;133(11):3423\u201333.","journal-title":"Brain"},{"issue":"2","key":"426_CR58","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/jnc.12073","volume":"124","author":"T Ducic","year":"2013","unstructured":"Ducic T et al. X-ray fluorescence analysis of iron and manganese distribution in primary dopaminergic neurons. J Neurochem. 2013;124(2):250\u201361.","journal-title":"J Neurochem"},{"issue":"12","key":"426_CR59","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00702-012-0873-0","volume":"119","author":"A Groger","year":"2012","unstructured":"Groger A, Berg D. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson\u2019s disease? Implications from MRI and TCS studies. J Neural Transm (Vienna). 2012;119(12):1523\u20138.","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"426_CR60","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jmri.21563","volume":"28","author":"LI Wallis","year":"2008","unstructured":"Wallis LI et al. MRI assessment of basal ganglia iron deposition in Parkinson\u2019s disease. J Magn Reson Imaging. 2008;28(5):1061\u20137.","journal-title":"J Magn Reson Imaging"},{"key":"426_CR61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1749-6632.2003.tb07476.x","volume":"991","author":"S Przedborski","year":"2003","unstructured":"Przedborski S, Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson\u2019s disease. Ann N Y Acad Sci. 2003;991:189\u201398.","journal-title":"Ann N Y Acad Sci"},{"issue":"19","key":"426_CR62","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jnnp.s1-5.19.195","volume":"5","author":"J Lhermitte","year":"1924","unstructured":"Lhermitte J, Kraus WM, McAlpine D. Original papers: on the occurrence of abnormal deposits of iron in the brain in parkinsonism with special reference to its localisation. J Neurol Psychopathol. 1924;5(19):195\u2013208.","journal-title":"J Neurol Psychopathol"},{"issue":"10","key":"426_CR63","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s11064-007-9346-5","volume":"32","author":"D Berg","year":"2007","unstructured":"Berg D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson\u2019s disease: implications for idiopathic and monogenetic forms. Neurochem Res. 2007;32(10):1646\u201354.","journal-title":"Neurochem Res"},{"issue":"12","key":"426_CR64","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrn983","volume":"3","author":"J Lotharius","year":"2002","unstructured":"Lotharius J, Brundin P. Pathogenesis of Parkinson\u2019s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci. 2002;3(12):932\u201342.","journal-title":"Nat Rev Neurosci"},{"key":"426_CR65","doi-asserted-by":"crossref","unstructured":"Hare DJ, Double KL. Iron and dopamine: a toxic couple. Brain. 2016.","DOI":"10.1093\/brain\/aww022"},{"issue":"5","key":"426_CR66","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1471-4159.2007.04976.x","volume":"103","author":"T Moos","year":"2007","unstructured":"Moos T et al. Iron trafficking inside the brain. J Neurochem. 2007;103(5):1730\u201340.","journal-title":"J Neurochem"},{"key":"426_CR67","doi-asserted-by":"crossref","unstructured":"Zucca FA, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease. Prog Neurobiol. 2015.","DOI":"10.1016\/j.pneurobio.2015.09.012"},{"key":"426_CR68","first-page":"81","volume":"5","author":"BX Wong","year":"2014","unstructured":"Wong BX, Duce JA. The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders. Front Pharmacol. 2014;5:81.","journal-title":"Front Pharmacol"},{"issue":"4","key":"426_CR69","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ana.23817","volume":"73","author":"S Ayton","year":"2013","unstructured":"Ayton S et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol. 2013;73(4):554\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"426_CR70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.2613","volume":"18","author":"P Lei","year":"2012","unstructured":"Lei P et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18(2):291\u20135.","journal-title":"Nat Med"},{"issue":"3","key":"426_CR71","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1139\/Y09-128","volume":"88","author":"O Kakhlon","year":"2010","unstructured":"Kakhlon O et al. Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol. 2010;88(3):187\u201396.","journal-title":"Can J Physiol Pharmacol"},{"issue":"5","key":"426_CR72","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/mrm.21951","volume":"61","author":"R Chamberlain","year":"2009","unstructured":"Chamberlain R et al. Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer\u2019s disease. Magn Reson Med. 2009;61(5):1158\u201364.","journal-title":"Magn Reson Med"},{"issue":"4","key":"426_CR73","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.neuroimage.2008.10.029","volume":"44","author":"B Yao","year":"2009","unstructured":"Yao B et al. Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. Neuroimage. 2009;44(4):1259\u201366.","journal-title":"Neuroimage"},{"issue":"9","key":"426_CR74","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/j.neurobiolaging.2015.05.022","volume":"36","author":"MM Zeineh","year":"2015","unstructured":"Zeineh MM et al. Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease. Neurobiol Aging. 2015;36(9):2483\u2013500.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"426_CR75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jsb.2005.11.001","volume":"153","author":"C Quintana","year":"2006","unstructured":"Quintana C et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer\u2019s disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol. 2006;153(1):42\u201354.","journal-title":"J Struct Biol"},{"issue":"4","key":"426_CR76","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.neurobiolaging.2013.10.078","volume":"35","author":"AC Crespo","year":"2014","unstructured":"Crespo AC et al. Genetic and biochemical markers in patients with Alzheimer\u2019s disease support a concerted systemic iron homeostasis dysregulation. Neurobiol Aging. 2014;35(4):777\u201385.","journal-title":"Neurobiol Aging"},{"key":"426_CR77","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1038\/ncomms7760","volume":"6","author":"S Ayton","year":"2015","unstructured":"Ayton S et al. Ferritin levels in the cerebrospinal fluid predict Alzheimer\u2019s disease outcomes and are regulated by APOE. Nat Commun. 2015;6:6760. Identifies that elevated brain iron adversely impacts on AD progression and introduces the concept that brain iron elevation is a possible mechanism for APOE\u03b544 being the major genetic risk factor for AD.","journal-title":"Nat Commun"},{"issue":"2","key":"426_CR78","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3233\/JAD-150797","volume":"51","author":"H Xu","year":"2016","unstructured":"Xu H et al. Iron regulates apolipoprotein E expression and secretion in neurons and astrocytes. J Alzheimers Dis. 2016;51(2):471\u201387.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"426_CR79","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ajmg.b.31053","volume":"153B","author":"JS Kauwe","year":"2010","unstructured":"Kauwe JS et al. Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer\u2019s disease. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(4):955\u20139.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"47","key":"426_CR80","doi-asserted-by":"crossref","first-page":"45518","DOI":"10.1074\/jbc.M207435200","volume":"277","author":"JT Rogers","year":"2002","unstructured":"Rogers JT et al. An iron-responsive element type II in the 5\u2032-untranslated region of the Alzheimer\u2019s amyloid precursor protein transcript. J Biol Chem. 2002;277(47):45518\u201328.","journal-title":"J Biol Chem"},{"issue":"6","key":"426_CR81","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.cell.2010.08.014","volume":"142","author":"JA Duce","year":"2010","unstructured":"Duce JA et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer\u2019s disease. Cell. 2010;142(6):857\u201367.","journal-title":"Cell"},{"issue":"12","key":"426_CR82","doi-asserted-by":"crossref","first-page":"e114174","DOI":"10.1371\/journal.pone.0114174","volume":"9","author":"BX Wong","year":"2014","unstructured":"Wong BX et al. Beta-amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One. 2014;9(12):e114174. Confirms that APP stabilises ferroportin on the neuronal surface and facilitates iron efflux despite lacking ferroxidase activity.","journal-title":"PLoS One"},{"issue":"3","key":"426_CR83","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3233\/JAD-2012-111169","volume":"30","author":"L Wan","year":"2012","unstructured":"Wan L et al. Overexpression of human wild-type amyloid-beta protein precursor decreases the iron content and increases the oxidative stress of neuroblastoma SH-SY5Y cells. J Alzheimers Dis. 2012;30(3):523\u201330.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"426_CR84","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1039\/c3mt00358b","volume":"6","author":"BE Needham","year":"2014","unstructured":"Needham BE, Ciccotosto GD, Cappai R. Combined deletions of amyloid precursor protein and amyloid precursor-like protein 2 reveal different effects on mouse brain metal homeostasis. Metallomics. 2014;6(3):598\u2013603.","journal-title":"Metallomics"},{"issue":"7","key":"426_CR85","doi-asserted-by":"crossref","first-page":"809","DOI":"10.15252\/embr.201338064","volume":"15","author":"RC McCarthy","year":"2014","unstructured":"McCarthy RC, Park YH, Kosman DJ. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep. 2014;15(7):809\u201315.","journal-title":"EMBO Rep"},{"issue":"1","key":"426_CR86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.freeradbiomed.2010.10.707","volume":"50","author":"L Wan","year":"2011","unstructured":"Wan L et al. Beta-amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med. 2011;50(1):122\u20139.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"426_CR87","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.neurobiolaging.2012.05.009","volume":"34","author":"C Guo","year":"2013","unstructured":"Guo C et al. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer\u2019s disease. Neurobiol Aging. 2013;34(2):562\u201375.","journal-title":"Neurobiol Aging"},{"issue":"1\u20132","key":"426_CR88","first-page":"102","volume":"16","author":"XW Su","year":"2015","unstructured":"Su XW et al. Serum ferritin is elevated in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1\u20132):102\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"426_CR89","doi-asserted-by":"crossref","first-page":"485723","DOI":"10.1155\/2014\/485723","volume":"2014","author":"C Veyrat-Durebex","year":"2014","unstructured":"Veyrat-Durebex C et al. Iron metabolism disturbance in a French cohort of ALS patients. Biomed Res Int. 2014;2014:485723. This is the first study to show a higher concentration of serum iron in ALS patients, strengthening the involvement of deregulated iron metabolism in ALS.","journal-title":"Biomed Res Int"},{"issue":"9","key":"426_CR90","doi-asserted-by":"crossref","first-page":"e45034","DOI":"10.1371\/journal.pone.0045034","volume":"7","author":"Y Nadjar","year":"2012","unstructured":"Nadjar Y et al. Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis. PLoS One. 2012;7(9):e45034.","journal-title":"PLoS One"},{"issue":"12","key":"426_CR91","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2169\/internalmedicine.51.7465","volume":"51","author":"K Ikeda","year":"2012","unstructured":"Ikeda K et al. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501\u20138.","journal-title":"Intern Med"},{"issue":"4","key":"426_CR92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/17482968.2012.665929","volume":"13","author":"A Ignjatovic","year":"2012","unstructured":"Ignjatovic A et al. Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler. 2012;13(4):357\u201362.","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"426_CR93","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/jmri.22185","volume":"31","author":"C Langkammer","year":"2010","unstructured":"Langkammer C et al. Mapping of iron deposition in conjunction with assessment of nerve fiber tract integrity in amyotrophic lateral sclerosis. J Magn Reson Imaging. 2010;31(6):1339\u201345.","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"426_CR94","doi-asserted-by":"crossref","first-page":"e35241","DOI":"10.1371\/journal.pone.0035241","volume":"7","author":"JY Kwan","year":"2012","unstructured":"Kwan JY et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One. 2012;7(4):e35241.","journal-title":"PLoS One"},{"issue":"3","key":"426_CR95","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1523\/JNEUROSCI.5443-08.2009","volume":"29","author":"SY Jeong","year":"2009","unstructured":"Jeong SY et al. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2009;29(3):610\u20139.","journal-title":"J Neurosci"},{"issue":"5","key":"426_CR96","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000323469","volume":"8","author":"Q Wang","year":"2011","unstructured":"Wang Q et al. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis. 2011;8(5):310\u201321.","journal-title":"Neurodegener Dis"},{"issue":"5","key":"426_CR97","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1440-1789.2010.01186.x","volume":"31","author":"T Haraguchi","year":"2011","unstructured":"Haraguchi T et al. Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome). Neuropathology. 2011;31(5):531\u20139.","journal-title":"Neuropathology"},{"key":"426_CR98","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.freeradbiomed.2013.01.032","volume":"62","author":"EJ Martinez-Finley","year":"2013","unstructured":"Martinez-Finley EJ et al. Manganese neurotoxicity and the role of reactive oxygen species. Free Radic Biol Med. 2013;62:65\u201375.","journal-title":"Free Radic Biol Med"},{"key":"426_CR99","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fnagi.2013.00023","volume":"5","author":"TR Guilarte","year":"2013","unstructured":"Guilarte TR. Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates. Front Aging Neurosci. 2013;5:23.","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"426_CR100","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1212\/01.wnl.0000247037.37807.76","volume":"67","author":"KJ Klos","year":"2006","unstructured":"Klos KJ et al. Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology. 2006;67(11):1984\u20139.","journal-title":"Neurology"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0426-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-016-0426-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0426-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T02:20:10Z","timestamp":1568427610000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-016-0426-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1007\/s11940-016-0426-1","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]},"article-number":"46"}}